KURA vs ORIC
KURA: Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships. ORIC: ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
Side-by-side fundamentals
| Metric | KURA | ORIC | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.54 | $10.75 | |
| Market cap as of 2026-07-23 | $944M | $1.1B | |
| PEG as of 2026-07-23 | -0.05 | n/a | |
| Net margin as of 2026-07-23 | -411.2% | n/a | |
| Gross margin as of 2026-07-23 | +99.9% | n/a | |
| Operating margin as of 2026-07-23 | -443.5% | n/a | |
| ROE as of 2026-07-23 | -141.9% | -35.3% | ORIC higher |
| ROA as of 2026-07-23 | -43.3% | -33.3% | ORIC higher |
| Debt / equity as of 2026-07-23 | 0.09 | 0.00 | ORIC lower |
| Revenue growth (YoY) as of 2026-07-23 | +29.5% | n/a | |
| Beta as of 2026-07-23 | 0.37 | 0.94 | |
| 1-year return as of 2026-07-22 close | +58.0% | -3.6% | KURA higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.